- Clinical Trials
- April 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- October 2024
- 196 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- May 2024
- 133 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- March 2024
- 164 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
Anal cancer drugs are a subset of colon cancer drugs, which are used to treat cancer of the rectum and anus. These drugs are typically used in combination with other treatments such as radiation therapy and surgery. Commonly used drugs include 5-fluorouracil, capecitabine, oxaliplatin, and irinotecan. These drugs work by targeting the cancer cells and preventing them from growing and spreading.
The anal cancer drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, AstraZeneca, and Eli Lilly. These companies are constantly developing new treatments and improving existing ones to provide better outcomes for patients. Show Less Read more